These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 33751807)
1. Piperazine, a Key Substructure for Antidepressants: Its Role in Developments and Structure-Activity Relationships. Kumar RR; Sahu B; Pathania S; Singh PK; Akhtar MJ; Kumar B ChemMedChem; 2021 Jun; 16(12):1878-1901. PubMed ID: 33751807 [TBL] [Abstract][Full Text] [Related]
2. Novel piperazine-2,5-dione analogs bearing 1H-indole: Synthesis and biological effects. Huang Z; Yin L; Guan L; Li Z; Tan C Bioorg Med Chem Lett; 2020 Dec; 30(24):127654. PubMed ID: 33144244 [TBL] [Abstract][Full Text] [Related]
3. A Profound Insight into the Structure-activity Relationship of Ubiquitous Scaffold Piperazine: An Explicative Review. Chaudhary J; Sharma V; Jain A; Sharma D; Chopra B; Dhingra AK Med Chem; 2024; 20(1):17-29. PubMed ID: 37815177 [TBL] [Abstract][Full Text] [Related]
4. Radioligand and computational insight in structure - Activity relationship of saccharin derivatives being ipsapirone and revospirone analogues. Kułaga D; Jaśkowska J; Satała G Bioorg Med Chem Lett; 2021 Jun; 42():128028. PubMed ID: 33839253 [TBL] [Abstract][Full Text] [Related]
5. Adjuvant therapy with antidepressants for the management of inflammatory bowel disease. Mikocka-Walus A; Prady SL; Pollok J; Esterman AJ; Gordon AL; Knowles S; Andrews JM Cochrane Database Syst Rev; 2019 Apr; 4(4):CD012680. PubMed ID: 30977111 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of the pharmacological descriptors related to the induction of antidepressant activity and its prediction by QSAR/QRAR methods. Avram S; Buiu C; Duda-Seiman D; Duda-Seiman C; Borcan F; Mihailescu D Mini Rev Med Chem; 2012 Jun; 12(6):467-76. PubMed ID: 22587763 [TBL] [Abstract][Full Text] [Related]
7. Piperazine analogs of naphthyridine-3-carboxamides and indole-2-carboxamides: novel 5-HT3 receptor antagonists with antidepressant-like activity. Dhar AK; Mahesh R; Jindal A; Bhatt S Arch Pharm (Weinheim); 2015 Jan; 348(1):34-45. PubMed ID: 25581677 [TBL] [Abstract][Full Text] [Related]
8. Quantitative structure-activity relationship analysis of aryl alkanol piperazine derivatives with antidepressant activities. Chen KX; Li ZG; Xie HY; Gao JR; Zou JW Eur J Med Chem; 2009 Nov; 44(11):4367-75. PubMed ID: 19581024 [TBL] [Abstract][Full Text] [Related]
9. Pharmacological treatment of unipolar depression. Anderson IM Curr Top Behav Neurosci; 2013; 14():263-89. PubMed ID: 22544348 [TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and evaluation of activity and pharmacokinetic profile of new derivatives of xanthone and piperazine in the central nervous system. Żelaszczyk D; Jakubczyk M; Pytka K; Rapacz A; Walczak M; Janiszewska P; Pańczyk K; Żmudzki P; Słoczyńska K; Marona H; Waszkielewicz AM Bioorg Med Chem Lett; 2019 Nov; 29(21):126679. PubMed ID: 31537425 [TBL] [Abstract][Full Text] [Related]
11. Synthetic Protocols, Structural Activity Relationship, and Biological Activity of Piperazine and its Derivatives. Faizan M; Kumar R; Mazumder A; Salahuddin ; Kukreti N; Kumar A; Chaitanya MVNL Med Chem; 2024; 20(8):753-780. PubMed ID: 38685782 [TBL] [Abstract][Full Text] [Related]
12. Duloxetine versus other anti-depressive agents for depression. Cipriani A; Koesters M; Furukawa TA; Nosè M; Purgato M; Omori IM; Trespidi C; Barbui C Cochrane Database Syst Rev; 2012 Oct; 10(10):CD006533. PubMed ID: 23076926 [TBL] [Abstract][Full Text] [Related]
13. Molecular Modelling of Potential Candidates for the Treatment of Depression. Silva DR; Barigye SJ; Santos-Garcia L; Fontes Ferreira da Cunha E Mol Inform; 2019 Jul; 38(7):e1900024. PubMed ID: 31131991 [TBL] [Abstract][Full Text] [Related]
14. Application of antidepressants in depression: A systematic review and meta-analysis. Yuan Z; Chen Z; Xue M; Zhang J; Leng L J Clin Neurosci; 2020 Oct; 80():169-181. PubMed ID: 33099342 [TBL] [Abstract][Full Text] [Related]
15. Synthesis and evaluation of sulfonyl piperazine LpxH inhibitors. Kwak SH; Cochrane CS; Ennis AF; Lim WY; Webster CG; Cho J; Fenton BA; Zhou P; Hong J Bioorg Chem; 2020 Sep; 102():104055. PubMed ID: 32663666 [TBL] [Abstract][Full Text] [Related]
17. Drug Development in Psychiatry: The Long and Winding Road from Chance Discovery to Rational Development. Preskorn SH Handb Exp Pharmacol; 2019; 250():307-324. PubMed ID: 30570691 [TBL] [Abstract][Full Text] [Related]
18. The Recent Development of Piperazine and Piperidine Derivatives as Antipsychotic Agents. Rathore A; Asati V; Kashaw SK; Agarwal S; Parwani D; Bhattacharya S; Mallick C Mini Rev Med Chem; 2021; 21(3):362-379. PubMed ID: 32912125 [TBL] [Abstract][Full Text] [Related]
19. LEVOMILNACIPRAN--A SUCCESSOR OF MILNACIPRAN WITH A HIGHER NORADRENERGIC SELECTIVITY. Zadka Ł; Dziwota E; Olajossy M Acta Pol Pharm; 2016; 73(2):285-9. PubMed ID: 27180420 [TBL] [Abstract][Full Text] [Related]
20. 2-Substituted N-aryl piperazines as novel triple reuptake inhibitors for the treatment of depression. Carter DS; Cai HY; Lee EK; Iyer PS; Lucas MC; Roetz R; Schoenfeld RC; Weikert RJ Bioorg Med Chem Lett; 2010 Jul; 20(13):3941-5. PubMed ID: 20570146 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]